Ahmed Mousa starts as the new CEO of Vicore tomorrow
Stockholm, September 8, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), announced today that Ahmed Mousa will begin as CEO of Vicore as of tomorrow, September 9, 2023.
Ahmed Mousa is an experienced biotechnology executive with deep expertise in business and corporate development across several therapeutic areas, including respiratory disease. He joins Vicore from Pieris Pharmaceuticals where he most recently served as Chief Business Officer.
Jacob Gunterberg, Chairman of the Board of Directors of Vicore, comments: “On behalf of the board, I am happy to welcome Ahmed as CEO of Vicore. We look forward to start working with him to further establish the company as a significant contributor in the development of treatments for pulmonary fibrosis. I would also like to thank Carl-Johan Dalsgaard for his excellent work in taking Vicore to the position it is in today.”
For further information, please contact:
Jacob Gunterberg, Chairman of Vicore
[email protected]
Optimum Strategic Communications
Mary Clark, Hana Malik, Zoe Bolt, Katie Flint
Phone: +44 20 3882 2119
E-mail: [email protected]
The information was submitted for publication, through the agency of the contact person set out above, on September 8, 2023 at 08:00 CEST.
About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF. C21 is protected by US and European orphan drug designation. A variety of patents have been filed to provide further protection for C21, out to 2040 and onwards. Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. Using its unique expertise in the ATRAG biology Vicore is further fueling its pipeline with several new small molecule drug assets, with long patent life and for a variety of indications, some of which could be partnered while others may be taken to the market by Vicore.
The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.
